1,000 Layoffs Expected At Novo Nordisk As US Pricing Pressures Bite
As a parting gift to Novo Nordisk staff, outgoing CEO Lars Rebien Sørensen has announced 1,000 job cuts at the company – around half in its home country of Denmark – in order to create a "sustainable balance between income and costs" in preparation for a challenging 2017.
You may also be interested in...
Increasing competition and pricing pressures in the US, have led Novo Nordisk to halve its profit growth expectations for 2017. In response, the diabetes drug developer plans to double-down on R&D efforts, expand into new therapy areas and seek external deals for early-stage assets to bulk up its pipeline.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.